A slice of half-baked remdesivir data takes a dark turn — but we're still waiting for a definitive study
We have another fuzzy snapshot of clinical trial data on Gilead’s remdesivir in coronavirus patients, and at first glance this one looks bleak for the most advanced therapy now in the clinic for Covid-19.
The Financial Times and STAT both reported on an abstract of the Chinese study, this one using a control group that appeared temporarily on the WHO site after it was posted accidentally. It’s still not been peer reviewed, but Salim Syed at Mizuho summarized the numbers:
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.